Literature DB >> 22133759

Lidocaine metabolites inhibit glycine transporter 1: a novel mechanism for the analgesic action of systemic lidocaine?

Robert Werdehausen1, David Kremer, Timo Brandenburger, Lukas Schlösser, Janusz Jadasz, Patrick Küry, Inge Bauer, Carmen Aragón, Volker Eulenburg, Henning Hermanns.   

Abstract

BACKGROUND: Lidocaine exerts antinociceptive effects when applied systemically. The mechanisms are not fully understood but glycinergic mechanisms might be involved. The synaptic glycine concentration is controlled by glycine transporters. Whereas neurons express two types of glycine transporters, astrocytes specifically express glycine transporter 1 (GlyT1). This study focuses on effects of lidocaine and its major metabolites on GlyT1 function.
METHODS: The effects of lidocaine and its metabolites monoethylglycinexylidide (MEGX), glycinexylidide, and N-ethylglycine on GlyT1 function were investigated in uptake experiments with [¹⁴C]-labeled glycine in primary rat astrocytes. Furthermore, the effect of lidocaine and its metabolites on glycine-induced currents were investigated in GlyT1-expressing Xenopus laevis oocytes.
RESULTS: Lidocaine reduced glycine uptake only at toxic concentrations. The metabolites MEGX, glycinexylidide, and N-ethylglycine, however, significantly reduced glycine uptake (P < 0.05). Inhibition of glycine uptake by a combination of lidocaine with its metabolites at a clinically relevant concentration was diminished with increasing extracellular glycine concentrations. Detailed analysis revealed that MEGX inhibits GlyT1 function (P < 0.05), whereas N-ethylglycine was identified as an alternative GlyT1 substrate (EC₅₀ = 55 μM).
CONCLUSIONS: Although lidocaine does not function directly on GlyT1, its metabolites MEGX and N-ethylglycine [corrected] were shown to inhibit GlyT1-mediated glycine uptake by at least two different mechanisms. Whereas N-ethylglycine [corrected] was demonstrated to be an alternative GlyT1 substrate, MEGX was shown to inhibit GlyT1 activity in both primary astrocytes and in GlyT1-expressing Xenopuslaevis oocytes at clinically relevant concentrations. These findings provide new insights into the possible mechanisms for the antinociceptive effect of systemic lidocaine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22133759     DOI: 10.1097/ALN.0b013e31823cf233

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  16 in total

1.  Intravenous lidocaine for effective pain relief after bimaxillary surgery.

Authors:  Uilyong Lee; Young-Jun Choi; Geun Joo Choi; Hyun Kang
Journal:  Clin Oral Investig       Date:  2017-02-06       Impact factor: 3.573

Review 2.  [Systemic effects of amide-linked local anesthetics : Old drugs, new magic bullets?]

Authors:  T Piegeler; R Werdehausen
Journal:  Anaesthesist       Date:  2018-07       Impact factor: 1.041

3.  Treatment of Neuropathic Pain.

Authors:  Matthew T Mendlik; Tanya J Uritsky
Journal:  Curr Treat Options Neurol       Date:  2015-12       Impact factor: 3.598

Review 4.  Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.

Authors:  Robert J Harvey; Benjamin K Yee
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

5.  Structural insights into the inhibition of glycine reuptake.

Authors:  Azadeh Shahsavar; Peter Stohler; Gleb Bourenkov; Iwan Zimmermann; Martin Siegrist; Wolfgang Guba; Emmanuel Pinard; Steffen Sinning; Markus A Seeger; Thomas R Schneider; Roger J P Dawson; Poul Nissen
Journal:  Nature       Date:  2021-03-03       Impact factor: 69.504

6.  Electroencephalographic changes associated with antinociceptive actions of lidocaine, ketamine, meloxicam, and morphine administration in minimally anaesthetized dogs.

Authors:  Ubedullah Kaka; Chen Hui Cheng; Goh Yong Meng; Sharida Fakurazi; Asmatullah Kaka; Atique Ahmed Behan; Mahdi Ebrahimi
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

7.  Intravenous infusion of lidocaine enhances the efficacy of conventional treatment of postherpetic neuralgia.

Authors:  Xinran Tan; Lulin Ma; Jie Yuan; Dexin Zhang; Jie Wang; Wenjing Zhou; Song Cao
Journal:  J Pain Res       Date:  2019-08-20       Impact factor: 3.133

8.  The lidocaine metabolite N-ethylglycine has antinociceptive effects in experimental inflammatory and neuropathic pain.

Authors:  Robert Werdehausen; Sebastian Mittnacht; Lucy A Bee; Michael S Minett; Anja Armbruster; Inge Bauer; John N Wood; Henning Hermanns; Volker Eulenburg
Journal:  Pain       Date:  2015-09       Impact factor: 7.926

9.  The GlyT1 Inhibitor Bitopertin Ameliorates Allodynia and Hyperalgesia in Animal Models of Neuropathic and Inflammatory Pain.

Authors:  Anja Armbruster; Elena Neumann; Valentin Kötter; Henning Hermanns; Robert Werdehausen; Volker Eulenburg
Journal:  Front Mol Neurosci       Date:  2018-01-10       Impact factor: 5.639

10.  Lidocaine as an element of multimodal analgesic therapy in major spine surgical procedures in children: a prospective, randomized, double-blind study.

Authors:  Ilona Batko; Barbara Kościelniak-Merak; Przemysław J Tomasik; Krzysztof Kobylarz; Jerzy Wordliczek
Journal:  Pharmacol Rep       Date:  2020-04-15       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.